Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Eur J Pharmacol ; 886: 173548, 2020 Nov 05.
Article in English | MEDLINE | ID: mdl-32926918

ABSTRACT

The global pandemic COVID-19, caused by novel coronavirus SARS-CoV-2, has emerged as severe public health issue crippling world health care systems. Substantial knowledge has been generated about the pathophysiology of the disease and possible treatment modalities in a relatively short span of time. As of August 19, 2020, there is no approved drug for the treatment of COVID-19. More than 600 clinical trials for potential therapeutics are underway and the results are expected soon. Based on early experience, different treatment such as anti-viral drugs (remdesivir, favipiravir, lopinavir/ritonavir), corticosteroids (methylprednisolone, dexamethasone) or convalescent plasma therapy are recommended in addition to supportive care and symptomatic therapy. There are several treatments currently being investigated to address the pathological conditions associated with COVID-19. This review provides currently available information and insight into pathophysiology of the disease, potential targets, and relevant clinical trials for COVID-19.


Subject(s)
Coronavirus Infections/complications , Coronavirus Infections/drug therapy , Molecular Targeted Therapy/methods , Pneumonia, Viral/complications , Pneumonia, Viral/drug therapy , COVID-19 , Clinical Trials as Topic , Humans , Pandemics
2.
J Control Release ; 309: 190-202, 2019 09 10.
Article in English | MEDLINE | ID: mdl-31356839

ABSTRACT

In recent times, molecular dynamic (MD) simulations have been applied in the area of drug delivery, as an in silico tool to predict the behaviour of nanoparticles with respect to their interaction with larger biological entities like bilayer membranes, DNA and dermal surface. However, the predictions must be systematically evaluated by extensive studies with actual biological entities in order to deem the in silico models accurate. Thus, in the present study, MD simulation was used to screen ligands with respect to ocular mucoadhesion. Mucin-4, a cell surface-associated mucin was selected as the substrate for the in silico study due to its abundance across the ocular surface. The ligands were then incorporated into a delivery system like nanostructured lipid carriers (NLC) and assessed for mucoadhesion by relevant in vitro and in vivo techniques. The in silico study suggested chitosan oligosaccharide (COS) to have an extensive mucoadhesive potential towards ocular mucin followed by stearylamine (STA) and cetrimonium bromide (CTAB) which showed intermediate and low mucoadhesion respectively. The corresponding in vitro assessment by spectrophotometry and nanoparticle tracking analysis showed a similar outcome wherein COS was found to be extensively mucoadhesive, followed by both STA and CTAB, which showed mucoadhesion to a nearly equal extent. The findings of in vivo confocal imaging following topical administration to rats showed that while COS and STA adhered extensively to the ocular surface, CTAB showed negligible adhesion. MD simulation was thus found to accurately predict interactions critical to mucoadhesion and the same could be fairly correlated well by relevant mucoadhesion studies both in vitro and in vivo.


Subject(s)
Drug Carriers/metabolism , Mucins/metabolism , Pharmaceutical Preparations/administration & dosage , Administration, Ophthalmic , Amines/metabolism , Animals , Cetrimonium/metabolism , Chitosan/analogs & derivatives , Chitosan/metabolism , Drug Delivery Systems , Eye/metabolism , Molecular Dynamics Simulation , Rats, Sprague-Dawley
3.
Eur J Pharm Sci ; 122: 51-63, 2018 Sep 15.
Article in English | MEDLINE | ID: mdl-29936087

ABSTRACT

The present work aims at improving stability of paclitaxel (PTX) loaded liposomes by its coating with silica on the surface by a modified sol-gel method. Effect of various components of liposomes such as phosphatidylcholine to cholesterol ratio (PC:CH), PTX and stearylamine on entrapment efficiency (% EE) and particle size were systematically investigated and optimized using central composite design on Design-Expert®. The optimized liposomes were utilized as a template for silica coating to prepare surface coated PTX liposils. Physical stability of liposomes and liposils was evaluated with Triton X-100 and the results indicated that liposils were much more stable as compared to liposomes and the same has been reiterated in stability study performed over 6 months. In vitro cytotoxicity study on B16F10 tumor cells showed cytotoxicity of PTX liposils was not significantly different than PTX liposomes, whereas both were less cytotoxic as compared to the commercial Taxol®. In vivo pharmacokinetics on rats, exhibited increased T1/2 of liposils when compared to liposomes and Taxol®, thus releasing the drug over a longer duration. The enhanced physicochemical stability as well as controlled release of PTX in liposils developed in this study could be an effective alternative to Taxol® and PTX liposomes.


Subject(s)
Antineoplastic Agents, Phytogenic/chemistry , Paclitaxel/chemistry , Silicon Dioxide/chemistry , Amines/administration & dosage , Amines/chemistry , Amines/pharmacokinetics , Animals , Antineoplastic Agents, Phytogenic/administration & dosage , Antineoplastic Agents, Phytogenic/pharmacokinetics , Cell Line, Tumor , Cell Survival/drug effects , Cholesterol/administration & dosage , Cholesterol/chemistry , Cholesterol/pharmacokinetics , Drug Liberation , Drug Stability , Erythrocytes/drug effects , Hemolysis/drug effects , Humans , Liposomes , Male , Melanoma, Experimental , Mice , Paclitaxel/administration & dosage , Paclitaxel/pharmacokinetics , Phosphatidylcholines/administration & dosage , Phosphatidylcholines/chemistry , Phosphatidylcholines/pharmacokinetics , Rats, Sprague-Dawley , Silicon Dioxide/administration & dosage , Silicon Dioxide/pharmacokinetics
SELECTION OF CITATIONS
SEARCH DETAIL
...